Cancer Cell

Papers
(The H4-Index of Cancer Cell is 105. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Accelerated approvals: Early-phase success or premature authorization?1720
KIT as a therapeutic target in neuroendocrine prostate cancer799
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer531
TAMing immunity through an unexpected source525
Diet-microbiome interactions in cancer494
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer384
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition374
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients367
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton358
Characterization of the generic mutant p53-rescue compounds in a broad range of assays351
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer324
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations302
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas297
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer291
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling280
Spatial profiling technologies illuminate the tumor microenvironment275
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron274
T cell dynamism and immune-related adverse events273
Cancer vaccines270
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer256
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma247
B cell heterogeneity in cancer comes of age246
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation242
Bacteria in metastatic sites: Unveiling hidden players in cancer progression239
A holistic view of cancer230
The aging lung microenvironment awakens melanoma metastases230
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion229
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target226
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors224
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses221
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer220
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity216
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer215
High endothelial venules in cancer: Regulation, function, and therapeutic implication215
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer213
Challenges in neoantigen-directed therapeutics213
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer212
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin209
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments194
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer193
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade192
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation191
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics189
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts188
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells188
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors184
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?183
Immunosensitivity cuts across mismatch repair status in colorectal cancer183
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma182
A genetic portrait of metastatic seeds in lung adenocarcinoma182
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma182
Challenges and opportunities for modeling aging and cancer179
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding178
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification175
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy175
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy174
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma172
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients169
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population165
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis163
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer154
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation147
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity146
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer144
Dissecting bulk transcriptomes of diffuse large B cell lymphoma143
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma143
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade141
ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy140
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis139
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies139
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers137
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells136
A path to translation: How 3D patient tumor avatars enable next generation precision oncology136
Tumor-infiltrating lymphocytes: A new hope135
Integrated proteogenomic characterization of glioblastoma evolution133
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma132
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes131
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma130
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness129
Midkine as a driver of age-related changes and increase in mammary tumorigenesis129
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring128
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions126
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD124
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1123
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment123
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells120
Immune determinants of the pre-metastatic niche119
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study118
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells117
Multiplex computational pathology for treatment response prediction116
Tumors on different wavelengths114
GDF15 research from bench to bedside113
Firing up neutrophil anti-tumor immunity with cocktails112
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy111
The winner takes it all: Competition drives clonal selection in gliomagenesis110
A circular RNA in neuroendocrine carcinomas110
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial110
New horizons at the interface of artificial intelligence and translational cancer research110
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers107
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma107
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer107
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma106
Proteogenomic data and resources for pan-cancer analysis105
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment105
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance105
0.062633991241455